A new study from Washington University suggests a straightforward blood test could act like a biological clock for Alzheimer’s, estimating both who’s at risk and roughly when symptoms might begin. Scientists tracked levels of a specific tau protein in hundreds of older adults and built a model that pairs age and protein measures to forecast symptom onset within a few years. The approach could change how clinical trials enroll people and how doctors spot high-risk patients long before memory problems surface. But the test is not ready for routine clinical use and researchers stress caution as they refine the method.
Researchers focused on a version of the tau protein called p-tau217, which forms “tangles” in the brain and interferes with nerve-cell communication. In healthy brains, tau stabilizes the structure of nerve cells, but when it misbehaves it becomes a signature of Alzheimer’s pathology. Brain scans can reveal these changes, but scans are costly and not always practical for large screenings. The team wanted to know if a blood marker could mirror those scans and offer a cheaper, easier option.
The study analyzed more than 600 older adults enrolled in long-term research programs, comparing blood samples to cognitive performance tracked over years. They found p-tau217 levels rise in a “remarkably consistent” pattern well before clinical signs show up. From that trend they built a model that uses a person’s age and p-tau217 level to estimate the year symptoms might begin, with a margin of error of three to four years. That kind of timeline could be powerful for planning early interventions and trials.
“We show that a single blood test measuring p-tau217 can provide a rough estimate of when an individual is likely to develop symptoms of Alzheimer’s disease,” lead author Kellen K. Petersen, PhD, instructor of neurology at Washington University in St. Louis, said. The data also revealed a striking age effect: those with abnormal p-tau217 at younger ages tended to have a much longer stretch before symptoms, while older people progressed more quickly after p-tau217 rose. “For example, people who first had abnormal p-tau217 levels around age 60 didn’t develop Alzheimer’s symptoms for about 20 years, whereas those who first had abnormal p-tau217 levels around age 80 developed symptoms after only about 10 years,” Petersen said.
Experts think that age-related changes in the brain influence how fast Alzheimer’s symptoms appear once pathology begins. “This could transform how researchers design clinical trials and, eventually, how clinicians identify people at highest risk for cognitive decline associated with Alzheimer’s years before decline begins,” Chicago-based Rebecca M. Edelmayer, PhD, vice president of scientific engagement at the Alzheimer’s Association, said. A blood test could lower costs and expand access compared with scans or spinal fluid tests, making early detection more practical.
“A blood test is generally much less expensive and easier to administer than a brain scan or spinal‑fluid test. In the future, it could help doctors and researchers identify people who may benefit from early treatments,” added Edelmayer. Still, the investigators were careful about limits: their models worked best for individuals whose p-tau217 readings fell within a particular range, and the study cohorts were relatively healthy, well-educated, and not very diverse. That raises concerns about how well the results translate to the general population.
“We were only able to make predictions for individuals whose p-tau217 levels fell within a certain range, although it was a fairly wide range,” Petersen shared. For now the team does not advise healthy, unimpaired people to chase biomarker testing at home. “At this point, we do not recommend that any cognitively unimpaired individuals have any Alzheimer’s disease biomarker test,” Dr. Suzanne Schindler, a neurologist at Washington University who was a co-author of the study, said.
Petersen also emphasized the work remains experimental and needs improvement before it can guide medical decisions. “The current estimate is not yet accurate enough for clinical use or personal medical decision-making, but we expect that it will be possible to create more accurate models,” he said. The group plans to explore additional blood and imaging markers and combine them with cognitive tests to tighten predictions and reduce error.
“There are many other blood and imaging biomarkers, as well as cognitive tests, that we can combine with plasma p-tau217 to improve the accuracy of predicting symptom onset,” Petersen said. “We hope this work will lead to even better models that will be useful to individuals.” Meanwhile, large trials are testing whether people with high p-tau217 can benefit from early treatment with drugs designed to reduce brain plaques, a move that could prove the value of predicting who to treat and when to start.
